neuroreha, Inhaltsverzeichnis neuroreha 2025; 17(01): 16-24DOI: 10.1055/a-2515-5986 Schwerpunkt Demenzdiagnose mittels Biomarker – geht das? Stefan Teipel Artikel empfehlen Abstract Artikel einzeln kaufen Volltext Referenzen Literatur 1 Jessen F, Frolich L. ICD-11: Neurocognitive Disorders. Fortschr Neurol Psychiatr 2018; 86: 172-177 2 American Psychiatric Association A. Diagnostic and statistical manual of mental disorders, DSM V. 5th. ed. Washington, DC, USA: American Psychiatric Publishing; 2013 3 Wyman-Chick KA, Chaudhury P, Bayram E. et al. Differentiating prodromal dementia with Lewy bodies from prodromal Alzheimerʼs disease: A pragmatic review for clinicians. Neurol Ther 2024; 13: 885-906 4 Rascovsky K, Hodges JR, Knopman D. et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134: 2456-2477 5 Folstein MF, Folstein SE, McHugh PR. Mini-mental-state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198 6 Kalbe E, Kessler J, Calabrese P. et al. DemTect: A new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry 2004; 19: 136-143 7 Nasreddine ZS, Phillips NA, Bedirian V. et al The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society 2005; 53: 695-699 JGS53221 [pii] 8 Shulman KI, Shedletsky R, Silver IL. The challenge of time: Clock drawing and cognitive function in the elderly. Int J Geriatr Psychiatry 1986; 1: 135-140 9 Petersen RC, Doody R, Kurz A. et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985-1992 10 Dubois B, Feldman HH, Jacova C. et al Research criteria for the diagnosis of Alzheimerʼs disease: Revising the NINCDS-ADRDA criteria. Lancet Neurology 2007; 6: 734-746 S1474-4422(07)70178-3 [pii] 11 Barker MS, Gottesman RT, Manoochehri M. et al. Proposed research criteria for prodromal behavioural variant frontotemporal dementia. Brain 2022; 145: 1079-1097 12 Sperling RA, Aisen PS, Beckett LA. et al Toward defining the preclinical stages of Alzheimerʼs disease: Recommendations from the National Institute on Aging-Alzheimerʼs Association workgroups on diagnostic guidelines for Alzheimerʼs disease. Alzheimers Dement 2011; 7: 280-292 S1552-5260(11)00099-9 [pii] 13 Jack CR, Bennett DA, Blennow K. et al. NIA-AA Research Framework: Toward a biological definition of Alzheimerʼs disease. Alzheimers Dement 2018; 14: 535-562 14 Bohlken J, Kostev K. Diagnostic and prescription behavior of general practitioners and specialist physicians in patients with dementia in 2005 and 2015 in Germany. Psychiatr Prax 2018; 45: 154-159 15 Lee JC, Kim SJ, Hong S. et al. Diagnosis of Alzheimerʼs disease utilizing amyloid and tau as fluid biomarkers. Exp Mol Med 2019; 51: 1-10 16 Dorey A, Perret-Liaudet A, Tholance Y. et al. Cerebrospinal fluid Abeta40 improves the interpretation of Abeta42 concentration for diagnosing Alzheimerʼs disease. Front Neurol 2015; 6: 247 17 Rostamzadeh A, Jessen F. Early detection of Alzheimerʼs disease and dementia prediction in patients with mild cognitive impairment: Summary of current recommendations. Nervenarzt 2020; 91: 832-842 18 Teipel SJ, Temp AGM, Lutz MW. Bayesian meta-analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high-dose gantenerumab in prodromal and mild Alzheimerʼs disease. Alzheimers Dement (N Y) 2024; 10: e12454 19 Klunk WE, Engler H, Nordberg A. et al. Imaging brain amyloid in Alzheimerʼs disease with Pittsburgh Compound-B. Annals of Neurology 2004; 55: 306-319 20 Villemagne VL, Pike KE, Chetelat G. et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Annals of Neurology 2011; 69: 181-192 21 Teipel S, Tang Y, Boccardi M. Predicting cognitive decline in older people by structural and molecular imaging. Curr Opin Neurol 2023; 36: 253-263 22 Teipel SJ, Spottke A, Boecker H. et al. Patient-related benefits of amyloid PET imaging in dementia: Rationale and design of the German randomized coverage with evidence development study ENABLE. Alzheimers Dement (N Y) 2023; 9: e12383 23 Zhu L, Zhao W, Chen J. et al. Systematic review and meta-analysis of diagnostic test accuracy (DTA) studies: The role of cerebral perfusion imaging in prognosis evaluation of mild cognitive impairment. Ann Palliat Med 2022; 11: 673-683 24 Smailagic N, Lafortune L, Kelly S. et al. 18F-FDG PET for prediction of conversion to Alzheimerʼs disease dementia in people with mild cognitive impairment: An updated systematic review of test accuracy. J Alzheimers Dis 2018; 64: 1175-1194 25 Lombardi G, Crescioli G, Cavedo E. et al. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimerʼs disease in people with mild cognitive impairment. Cochrane Database Syst Rev 2020; 3: CD009628 26 Li H, Habes M, Wolk DA. et al. A deep learning model for early prediction of Alzheimerʼs disease dementia based on hippocampal magnetic resonance imaging data. Alzheimers Dement 2019; 15: 1059-1070 27 Palmqvist S, Tideman P, Cullen N. et al. Prediction of future Alzheimerʼs disease dementia using plasma phospho-tau combined with other accessible measures. Nature Medicine 2021; 27: 1034-1042 28 Devanarayan V, Doherty T, Charil A. et al. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimerʼs disease. Alzheimers Dement 2024; 20: 5617-5628 29 Zhang S, Smailagic N, Hyde C. et al. (11)C-PIB-PET for the early diagnosis of Alzheimerʼs disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2014; 7: CD010386 30 Martinez G, Vernooij RW, Fuentes Padilla P. et al. 18F PET with flutemetamol for the early diagnosis of Alzheimerʼs disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2017; 11: CD012884 31 Martinez G, Vernooij RW, Fuentes Padilla P. et al. 18F PET with florbetapir for the early diagnosis of Alzheimerʼs disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2017; 11: CD012216 32 Martinez G, Vernooij RW, Fuentes Padilla P. et al. 18F PET with florbetaben for the early diagnosis of Alzheimerʼs disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2017; 11: CD012883 33 Ruan D, Sun L. Amyloid-beta PET in Alzheimerʼs disease: A systematic review and Bayesian meta-analysis. Brain Behav 2023; 13: e2850
